维格列汀在2型糖尿病治疗中的应用

摘要

Vildagliptin is a potent and specific inhibitor of dipeptidyl peptidase 4,which has been implicated to enhance and prolong the physiological actions of incretion hormones including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.Vildagliptin is an orally administered drug and has been licensed for the treatment of type 2 diabetes mellitus.Vildagliptin monotherapy or in combination with other drugs can effectively lower glycosylated haemoglobin levels to a great extent.In addition,vildagliptin acts in a glucose-dependent manner,explaining its low risk of hypoglycemia.This drug has been proved well tolerated with few gastrointestinal side effects or oedema.Therefore vildagliptin is a promising new option for type 2 diabetic patients,and these patients would achieve better glycemic control and fewer complications in the long run.%维格列汀是一种强效的特异性二肽基肽酶4抑制剂,通过抑制二肽基肽酶4对胰升糖素样肽l和葡萄糖依赖性促胰岛素分泌多肽的降解作用发挥效应.维格列汀为口服制剂,已经被批准治疗2型糖尿病.单药使用维格列汀或联合其他药物可以有效降低患者HbA1C水平.此外由于维格列汀降糖作用是血糖依赖性的所以低血糖发生率低,其不良反应如胃肠道反应和水肿发生率低,因此绝大多数患者对该药耐受良好.所以,维格列汀是2型糖尿病患者新的选择,良好的血糖控制可让患者减少远期并发症.